title: Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
abstract: OBJECTIVE
  The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel) in the treatment of patients with previously treated metastatic breast cancer in Spain.
  
  
  METHODS
  Efficacy data were obtained from the CA012 trial (nab-paclitaxel administered every 3 weeks [q3w] and sb-paclitaxel q3w) and indirect comparison (sb-paclitaxel administered weekly), and were modeled to a time horizon of 5 years using a Markov model. The analysis was performed from the National Health Service perspective. Use of resources and key assumptions of the model were validated by a panel of 22 local oncologists.
  
  
  RESULTS
  Compared with sb-paclitaxel q3w, nab-paclitaxel q3w was cost effective, with a cost per life year gained of €11,088 and a cost per quality-adjusted life year of €17,808. Compared with sb-paclitaxel administered weekly, it showed savings of €711 per patient.
  
  
  CONCLUSIONS
  The COSTABRAX study showed that nab-paclitaxel q3w is a cost-effective alternative compared with sb-paclitaxel q3w and a cost-saving alternative to sb-paclitaxel administered weekly in Spain.
authors.affiliation: Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
authors.forename: Emilio
authors.initials: E
authors.lastname: Alba
authors.forename: Eva
authors.initials: E
authors.lastname: Ciruelos
authors.forename: Rafael
authors.initials: R
authors.lastname: López
authors.forename: José Manuel
authors.initials: JM
authors.lastname: López-Vega
authors.forename: Ana
authors.initials: A
authors.lastname: Lluch
authors.forename: Miguel
authors.initials: M
authors.lastname: Martín
authors.forename: Montserrat
authors.initials: M
authors.lastname: Muñoz
authors.forename: Pedro
authors.initials: P
authors.lastname: Sánchez-Rovira
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Seguí
authors.forename: Marta Rubio
authors.initials: MR
authors.lastname: Liria
authors.forename: Ferran
authors.initials: F
authors.lastname: Pérez-Alcántara
mesh_terms: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D002368:Castor Oil / Q000031:analogs & derivatives / Q000737:chemistry; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D053758:Nanoparticles; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; C023040:polyethoxylated castor oil; D002368:Castor Oil; D017239:Paclitaxel